LUPIN
|
LUPIN Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 42.01 | 9.45 | -33.62 | 26.81 | -5.95 |
| CEPS(Rs) | 68.74 | 29.20 | 3.29 | 46.62 | 12.59 |
| DPS(Rs) | 8.00 | 4.00 | 4.00 | 6.50 | 6.00 |
| Book NAV/Share(Rs) | 311.08 | 270.67 | 263.84 | 300.06 | 272.01 |
| Tax Rate(%) | 20.09 | 37.52 | -9.99 | 26.75 | 152.81 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.94 | 6.05 | 0.73 | 9.08 | 7.87 |
| EBIT Margin(%) | 8.61 | 3.48 | -4.14 | 6.43 | 3.74 |
| Pre Tax Margin(%) | 7.63 | 2.52 | -4.62 | 5.93 | 2.53 |
| PAT Margin (%) | 6.10 | 1.57 | -5.09 | 4.34 | -1.34 |
| Cash Profit Margin (%) | 9.87 | 4.67 | 0.50 | 7.48 | 1.91 |
| Performance Ratios | |||||
| ROA(%) | 8.33 | 2.01 | -6.70 | 5.09 | -1.54 |
| ROE(%) | 14.61 | 3.68 | -11.79 | 9.47 | -3.09 |
| ROCE(%) | 16.24 | 6.06 | -7.11 | 9.71 | 5.45 |
| Asset Turnover(x) | 1.37 | 1.28 | 1.32 | 1.17 | 1.15 |
| Sales/Fixed Asset(x) | 1.68 | 1.67 | 1.93 | 1.96 | 2.00 |
| Working Capital/Sales(x) | 6.42 | 8.93 | 7.10 | 5.09 | 4.84 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.59 | 0.60 | 0.52 | 0.51 | 0.50 |
| Receivable days | 52.75 | 56.09 | 53.73 | 64.06 | 64.63 |
| Inventory Days | 54.32 | 58.53 | 53.64 | 48.75 | 44.49 |
| Payable days | 177.49 | 144.07 | 132.55 | 161.68 | 163.62 |
| Valuation Parameters | |||||
| PER(x) | 38.51 | 68.54 | - | 38.08 | - |
| PCE(x) | 23.54 | 22.19 | 227.04 | 21.90 | 46.84 |
| Price/Book(x) | 5.20 | 2.39 | 2.83 | 3.40 | 2.17 |
| Yield(%) | 0.49 | 0.62 | 0.54 | 0.64 | 1.02 |
| EV/Net Sales(x) | 3.76 | 1.95 | 2.23 | 3.26 | 1.99 |
| EV/Core EBITDA(x) | 19.13 | 17.33 | 85.46 | 18.26 | 10.77 |
| EV/EBIT(x) | 27.50 | 32.73 | -29.81 | 27.16 | 27.28 |
| EV/CE(x) | 4.43 | 1.94 | 1.69 | 2.11 | 1.23 |
| M Cap / Sales | 3.68 | 1.77 | 2.07 | 3.05 | 1.74 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 20.25 | 1.44 | 8.19 | -1.38 | 4.84 |
| Core EBITDA Growth(%) | 110.03 | 336.33 | -84.13 | -4.77 | -1.91 |
| EBIT Growth(%) | 175.93 | 180.59 | -167.66 | 62.21 | -34.55 |
| PAT Growth(%) | 332.35 | 129.66 | -222.92 | 407.07 | -176.75 |
| EPS Growth(%) | 344.46 | 128.11 | -225.39 | 550.89 | -144.36 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.19 | 0.34 | 0.32 | 0.35 | 0.51 |
| Current Ratio(x) | 1.58 | 1.34 | 1.51 | 1.66 | 1.67 |
| Quick Ratio(x) | 1.00 | 0.86 | 0.95 | 1.17 | 1.30 |
| Interest Cover(x) | 8.77 | 3.61 | -8.61 | 12.92 | 3.09 |
| Total Debt/Mcap(x) | 0.04 | 0.14 | 0.11 | 0.10 | 0.24 |
Compare Financial Ratios of peers of LUPIN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LUPIN | ₹91,634.6 Cr | 3.3% | -1.7% | 22.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹405,068.0 Cr | 1.4% | 0.1% | 13.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹177,105.0 Cr | 0.8% | 12.3% | 47.2% | Stock Analytics | |
| CIPLA | ₹122,016.0 Cr | 2.6% | -0.1% | 0.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,651.0 Cr | 7.8% | 12.9% | 13.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹108,942.0 Cr | 2.7% | -0.6% | 14.4% | Stock Analytics | |
LUPIN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LUPIN | 3.3% |
-1.7% |
22.3% |
| SENSEX | 2.1% |
3.7% |
14.3% |
You may also like the below Video Courses
